title: Cyclo-oxygenase 2 inhibitor, nabumetone, inhibits proliferation in chronic myeloid leukemia cell lines.
abstract: The anti-tumor effect of cyclo-oxygenase (COX) inhibitors has been documented in several studies. COX2 inhibitors have attracted more attention because of the fewer side-effects and the more prominent anti-tumor effects. However, experience with these drugs in hematological malignancies is limited. In our study, a potent COX2 inhibitor, nabumetone (NBT), was investigated for its anti-proliferative and apoptotic effects in K-562 and Meg-01 chronic myeloid leukemia blastic cell lines as a single agent or in combination with adriamycin (ADR) and interferon alpha (IFN-a). In these cell lines, a dose-dependent inhibition of proliferation was observed with NBT. We observed no significant apoptotic effect of NBT. However, NBT potentiated the apoptotic effect of ADR in the K-562 cell line. Bcl-2 expression was reduced by NBT (11% vs. 2%). The combination of NBT with IFN did not have any significant effect on the K-562 cell line. We suggest that NBT inhibits proliferation and potentiates the apoptotic effect of ADR in chronic myeloid leukemia cell lines.
authors: Department of Internal Medicine, Division of Hematology-Oncology, School of Medicine, Dokuz Eylul University, Izmir, Turkey.
authors: Filiz
authors: F
authors: Vural
authors: Mehmet Ali
authors: MA
authors: Ozcan
authors: Güner Hayri
authors: GH
authors: Ozsan
authors: Halil
authors: H
authors: Ateş
authors: Fatih
authors: F
authors: Demirkan
authors: Ozden
authors: O
authors: Pişkin
authors: Bülent
authors: B
authors: Undar
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D002074:Butanones / Q000494:pharmacology*; D045744:Cell Line, Tumor; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D004317:Doxorubicin / Q000008:administration & dosage; D004354:Drug Screening Assays, Antitumor; D005434:Flow Cytometry; D006801:Humans; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000077430:Nabumetone; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis
chemical_list: D000970:Antineoplastic Agents; D002074:Butanones; D016861:Cyclooxygenase Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D004317:Doxorubicin; D000077430:Nabumetone